NCT06532942 - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

(Part A) MKND-201

Participants will receive single ascending doses (Target Dose, High Dose, and Very High Dose) of MKND-201 or placebo administered via oral inhalation on Day 1

DRUG

Placebo

Participants will receive matching placebo across Part A and Part B of the study.

DRUG

(Part B) MKND-201

Participants will receive multiple ascending doses (Target Dose and High Dose) of MKND-201 or placebo administered via oral inhalation, twice daily, from Day 1 to Day 7

Trial Locations (1)

78229

RECRUITING

Flourish Research, San Antonio